The determinant of poor prognostic factors in patients with primary intracerebral hemorrhage

Rizaldy Taslim Pinzon, Andra Kurniawan

Department of Neurology, Faculty of Medicine Duta Wacana Christian University, Yogyakarta

ABSTRACT

Background: Stroke is leading cause of death in Indonesia. The mortality rates of patients' hemorrhage stroke are higher than ischemic stroke. The understanding of prognostic factors can help the clinician for further management. The previous studies of a prognostic factor for hemorrhagic stroke in Indonesia are still very limited. **Aim:** The aim of this study is to measure determinant factors of mortality in patients with primary intracerebral hemorrhage. **Methods:** A nested case-control method is used in this study. The study subjects were obtained from the stroke registry from stroke unit at Bethesda Hospital Yogyakarta between 2015 and 2017. Data were analyzed using univariate, bivariate, and multivariate logistic regression analysis. **Results:** The data obtained from 128 intracerebral hemorrhage stroke patients which consist of 74 males (57/8%) and 54 females (42.2%). This study showed that significant prognostic factors are level of consciousness (Glasgow Coma Scale level ≤ 8) (OR: 22.41, 95% confidence interval [CI]: 4.461-112.587, P < 0.001, leukocyte count (odds ratio [OR]: 4.894, 95% CI: 1.480-16.179, P = 0.009), and the presence of complications (OR: 3.502, 95%CI: 1.103-11.117, P = 0.033). **Conclusion:** This study showed that unconsciousness, high leukocyte count, and the presence of complications will increase the risk of inhospital mortality.

Key words: Clinical predictor, Intracerebral hemorrhage stroke, Mortality, Prognosis

INTRODUCTION

Stroke is leading cause of death and disability worldwide. The ischemic stroke rate is higher than hemorrhagic stroke.^[1] Even the rate is lower compared with ischemic stroke, the mortality rate is much higher in hemorrhagic stroke.^[2] The previous study showed that there are several prognostic factors in primary intracerebral hemorrhage.^[3] Some previous studies determined the scoring system for poor prognosis in hemorrhagic stroke.^[4] The data about intracerebral hemorrhagic prognosis are limited.

Understanding about prognostic factors in hemorrhagic stroke will help clinician for appropriate management of the patients.^[3] It will also facilitate clinician to give education about the prognosis for the family. Previous studies about the prognostic factors in hemorrhagic stroke in Indonesia are very limited. The aim of this study is to measure the determinant factors of mortality in patients with hemorrhagic stroke.

METHODS

Design

The design of this study is nested case–control. The outcome of this study is inhospital mortality. The case is defined as patients who died during hospitalization. The control group is patients who alive in hospital discharge. We only use complete data. Patients who discharge against medical advice and patients who being refer to other hospital were excluded from the study.

Subject

The subjects of this study are patients with hemorrhagic stroke that confirmed with clinical and radiological finding. The inclusion criteria are as follows: Hemorrhagic stroke patients, age > 40 years old, and first-time stroke. We exclude patients with a history of previous stroke. We also exclude patients that being referred from other hospital. Patients with incomplete data are excluded. We use OpenEpi software to calculate the sample size with a significance level <0.05 and power 0.8.

Variables

The dependent variable in this study is inhospital mortality. The independent variables are demographic profile and clinical characteristics. The data about demographic profile consist of age and sex. The data about clinical characteristics profile consist of onset to hospital admission, comorbidities, and stroke risk factors. We also consider clinical symptoms and inhospital complications as independent variables.

Ethic

This study used secondary data. Research Ethics Committee of Duta Wacana Christian University School of Medicine has approved the study.

Statistical Analysis

The statistical analysis was performed by licensed SPSS software. We considered that significance level is P < 0.05. The data analyzed univariate and bivariate. The bivariate analysis was performed

Address for Correspondence:

Rizaldy Taslim Pinzon, Faculty of Medicine Duta Wacana Christian University, Jl. Dr. Wahidin Sudirohusodo 5–25, Yogyakarta 55224, Indonesia. E-mail: drpinzon17@gmail.com

Received: 15-10-2017, Revised: 30-10-2017, Accepted: 14-12-2017

with Chi-square. The multivariate analysis was performed with logistic regression.

RESULT

The data obtained from 128 patients with hemorrhagic stroke that consist of 74 male (57.8%) and 54 female (42.2%). The most common age ranges from 51 to 60 years old (35.2%). The most common onset to hospital admission is between 3 and 6 h after onset (30.5%). Almost half (42.2%) of the patients are unconscious (Glasgow coma scale [GCS] <8) in hospital admission. High leukocyte count in hospital admission was present in 56.3% of cases. The most prominent risk factor is hypertension and present in 79.7% of cases. Table 1 summarized the baseline characteristic of the study subjects.

Table 2 presented the risk factors of mortality in patients with primary intracerebral hemorrhage. This table showed that elderly, unconsciousness, and the presence of complications will increase the risk of mortality.

The significant risk factors will be further analyzed in multivariate analysis. Logistic regression approach will be used for multivariate analysis. The significant prognostic factors in bivariate analysis are as follows: Age, level of consciousness, leukocyte count, and the presence of complications Table 3.

DISCUSSION

The multivariate analysis showed that GCS <8, high leukocyte count on hospital admission, and the presence of complications significantly increase the mortality. The mortality of patients with GCS ≤8 is significantly higher compared with conscious patients on hospital admission (odds ratio [OR]: 22.41, 95% confidence interval [CI]: 4.461–112.587, P < 0.001). The patients with complications have higher mortality rate compared without complications (OR: 3.502, 95% CI: 1.103–11.117, P = 0.033). The medical and neurological complications in patients with stroke are common (gastrointestinal [GI] bleeding, pneumonia,

Table 1: Baseline characteristics of study subject		
Baseline characteristics	<i>n</i> =128 (%)	
Sex		
Male	74 (57.8)	
Female	54 (42.2)	
Age (years)		
40–50	26 (20.3)	
51–60	45 (35.2)	
61–70	29 (22.7)	
>70	28 (21.9)	
Onset to hospital admission (hours)		
<3	20 (15.6)	
3–6	39 (30.5)	
6–12	26 (20.3)	
12-24	11 (8.6)	
>24	32 (25.5)	
Level of consciousness		
15	40 (31.3)	
13-14	12 (9.4)	
	(Contd	

Table 1: (Continued)

Baseline characteristics	<i>n</i> =128 (%)
9–12	22 (17.2)
≤8	54 (42.2)
Systolic Blood Pressure (mmHg)	
≤129	8 (6.3)
130–139	9 (7.0)
≥140	111 (86.7)
Diastolic blood pressure (mmHg)	
≤84	28 (21.9)
85-89	0(0)
≥90 Dandom blood alucase on bacnital admission	100 (78.1)
	112 (87 5)
>200	112 (07.5) 16 (12 д)
Leukocyte count	10 (12.5)
≤11	56 (43.8)
>11	72 (56.3)
Atrial fibrillation	
Yes	4 (3.1)
No	124 (96.9)
Diabetes mellitus	
Yes	26 (20.3)
No	102 (79.7)
Hypertension	
Yes	102 (79.7)
No	26 (20.3)
Dyslipidemia	(0)
Yes	10 (7.8)
NO	118 (92.2)
Present	62(48.4)
Absent	66 (51 6)
Side of weakness	00 (5210)
None	20 (15.6)
Left	54 (42.2)
Right	42 (32.8)
Both side	12 (9.4)
Muscle strength (MRC Scale)	
Normal (5)	8 (6.3)
4	16 (12.5)
3	13 (10.2)
2	43 (33.6)
1	27 (21.1)
0 Caralian	21 (16.4)
Smoking	
No	29 (22.7)
Length of hospital stay (days)	99 (77-3)
	(s (s (s)
-5	79 (61.7)
Metabolic encepalopathy	13 (17
Yes	14 (10.9)
No	114 (89.1)
Heart failure	
Yes	4 (3.1)
No	124 (96.9)
Ventilator assisted	
Yes	12 (9.4)
No	116 (90.6)

MRC: Medical research council

<table-container>National (4)Deed (64)Alive (64)ORCf.PBr</table-container>	Table 2: The risk factors of mortality in patients with primary intracerebral hemorrhage					
Sec. Period Constrained Sec. Period Sec.	Variable	Dead (64)	Alive (64)	OR	CI	Р
Frank Male App (ward)9491Ref0.32App (ward)3300.5070.394-1.321App (ward)14314.181.34-13.37G-7014200.352-6.570.00977014202.490.557-6.5777014202.466.59-9.073*146Ref0.5903*14202.460.59-9.073*14182.070.65+1.16151212120.65+1.1610-7412130.65+1.1511-741562.600.65+1.3612-741370.55+1.360.053*14182.770.65+1.3613-741573.370.654-7.3613-741573.370.654-7.3613-741573.370.654-7.3625001573.370.654-7.362510173.370.654-7.360.03251013773.57340573.370.554-7.3625101373.670.3925101373.670.39251014770.5340010.332510131470.3325101471.50.3925101514100.39 <td>Sex</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Sex					
Main App (var)330,5370.394-1.31.40-590379Ref0.00950-6014314.381.34-3.3750-60130142.780.55 6.572014142.780.55 6.572014142.780.55 6.5721142.780.55 6.570.50023-6130142.770.56+1.363-113142.770.56+1.3624.4130162.460.69-5.076-13131142.770.56+1.3624.4130162.450.654/1.376-13131157.38.8f25.4142.770.554/1.37.6424.4157.30.554/1.37.6425.4157.30.554/1.37.64313142.710.554/1.37.64313142.710.554/1.37.64313157.70.33314157.70.3325.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.3525.4100-19100-9.35	Female	41	31	Ref		0.152
App (vers) 0 - 5079Ref0.0090 - 5014314.18 $1.34 - 1.37$ 0.0090 - 7019100.990.21 - 3.500.35 - 6.57714120.990.25 - 6.570.0093 - 570.022.460.65 - 1.50.0093 - 6139202.460.65 - 1.50.0093 - 6139202.460.65 - 1.50.0093 - 6139202.460.65 - 1.50.0093 - 513142.70.65 - 1.30.0093 - 4573.370.62 - 3.7640.0013 - 34573.370.62 - 3.7640.0013 - 44573.370.62 - 3.7640.0013 - 34693.5717.964 - 69.7930.0013 - 34693.5710.32 - 5.67 - 7.360.0013 - 34693.650.300.35 - 6.373 - 34693.650.390.35 - 6.373 - 34993.650.390.35 - 6.373 - 3260.300.35 - 6.370.383 - 3260.390.35 - 6.300.373 - 3260.390.35 - 6.300.353 - 3260.390.35 - 6.300.353 - 3260.390.35 - 6.300.363 - 3260.390.35 - 6.300.36 <td>Male</td> <td>23</td> <td>33</td> <td>0.597</td> <td>0.294-1.121</td> <td>5</td>	Male	23	33	0.597	0.294-1.121	5
A-50 -5-6017 -149 -14Ref0.009 -14-35050 -5-7013 -140.099 -0.9990.31-350 -0.55670.009 -0.25670-rest(hours)0.596-3 -5-6014 -140.69-9.07 -0.5860.596-3-1 -5-60121 -14 -1222.46 -0.68-1.260.69-9.07 -0.586-3-14 -2-4 -2-4121 -14 -2-7 -2-40.68-1.27 -0.824-1376 -0.924-1399-0.025 -0.924-1399 -0.924-139	Age (years)	3	55	557	51	
3-614134.181.14-1.33.7105-7014140.090.28-3.00.55-6.577014141890.55-6.573146Ref0.59-9.073-519202.460.69-9.073-5419202.460.69-9.073-419202.460.69-9.073-419202.460.69-9.073-419202.460.69-9.073-419202.460.69-9.073-419203.740.68-13.26519330.68-13.260.68-13.263-141573.3670.88-13.37,6462073.3670.68-13.36,463-141573.3670.68-13.36,463-13673.3670.68-13.36,463-141573.3670.68-13.36,463-13107Ref0.33-36,463-1410100.030.033-14100.030.033-2541Ref0.0342001214160.0342001214160.34-30.662001214160.062001214160.34-30.6620013141616200131314162101416161	40-50	17	9	Ref		0.009
6-70190000.38-3077014141.890.38-3073146Ref0.3003-6192.3460.69-9.076-1212142.730.68-13.262-24562.800.48-13.262-24562.800.48-13.262-24563.800.48-13.263-2473.3Ref3-2473.3Ref3-3473.3Ref9-3273.3Ref9-3473.3Ref9-3473.3Ref9-3473.3Ref9-3277.93.3Ref314693.35717.96(+5).7639-3277.9Ref313890.10-0.9323006.34.80.110-0.932301890.30.51.0223026.34.80.110-0.9323030.51.0280.3100.31.985-89900.30.31.985-8990.30.31.90.31.985-89913.0980.31.4-3.0509.31013.0980.31.4-3.05080.31.085-8913.0980.34.9-3.0540.0569.31011 <td< td=""><td>51-60</td><td>14</td><td>31</td><td>4.18</td><td>1.34-13.37</td><td>-</td></td<>	51-60	14	31	4.18	1.34-13.37	-
yp'n14141890.55-6.37Onset (hours)0.5003146Ref0.5003-619202.460.69-9.073-61302.720.68-11.36-13-24563.800.8-17.363-741242830.8-17.363-74573.3670.84.17.063-74573.3670.84.17.063-74573.3670.65.47.3963-916573.3670.65.47.3963-926573.3670.65.47.3963-930.17Ref<0.02.1	61-70	19	10	0.99	0.28-3.50	
Onser floway16Ref0.5003-6129202.460.69-9.070.5006-12121121142.720.68-13.613-2456.42.800.48-13.610.69-9.073-242.112142.800.48-13.613-2412130.80-13.710.80-13.713-3473.3Ref0.80-13.713-3473.3Ref0.80-13.713-3473.3Ref0.80-13.713-3473.35/70.65.47.3960.133-34673.3Ref0.80-13.713-34673.36/70.83-13.713-346992.50.13-85.463-349992.50.13-85.463-39092.50.13-85.463-39092.50.37-85.463-3499993-449993-450.390.35-1.023-46993.4623-306260Ref2006260Ref2006260Ref3-31493.0980.34-90.6683-31133.0980.34-90.6683-31148.60.34-90.668No5076.0073-31148.60.34-90.668No1010<	>70	14	14	1.89	0.55-6.57	
s3146Ref0.9003-419201.4,60.69-0.003-419142.7/20.68-13.2612-242,40,41830.80-1.713-242,40,41830.80-1.71GCS on admission	Onset (hours)			-		
9-619202,40.69-9.076-3212142,720.69-9.076-3212142,720.69-1.12.63-24,14182.800.44-1.7.2654141830.80-1.17.155733Ref0.80-1.7.115733Ref0.80-1.7.113-44273.3670.52-4.7.3.76.40.00.13-3473.3670.52-4.7.3.76.40.00.13-4473.20.66-4.7.3.960.00.13-347152.20.3-65.460.00.130-33092.50.33-65.460.33310-3390990.35-1.020.38320-300.5450.390.35-1.020.3932115450.390.35-1.020.3932025450.390.35-1.020.03332025450.390.35-1.020.03332025450.390.35-1.020.01321150.390.35-1.020.010.01321153.0480.300.300.3032025450.390.35-1.020.01321150.300.300.300.3032025583.249-2.75.960.300.3032032303.030.300.30321150.32-1	<3	14	6	Ref		0.500
G-1212142.720.68-11.2613-24141830.80-11.71GCS on admission33-14573.3670.82-13.76433-14573.3670.82,13.76439-1273.3670.82,13.76439-1317Ref<	3–6	19	20	2.46	0.69-9.07	
12-24 >224 224 3255 6 62.80 2.80 3.80-13,71 3.80 3.80-13,71 3.80 3.80-13,71 3.80 3.80-13,71 3.80 3.80-13,71 3.80 3.80-13,71 3.80 3.80-13,71 3.80 3.80-13,71 3.80	6–12	12	14	2.72	0.68–11.26	
224 GCS on admission141830.80-11,71GCS on admission	12-24	5	6	2.80	0.48–17.26	
GCS analmissionvvv <td>>24</td> <td>14</td> <td>18</td> <td>3</td> <td>0.80–11.71</td> <td></td>	>24	14	18	3	0.80–11.71	
15 33-14 33-14 33-14 33-14 33-14 31-147 7 33 1Ref0.82-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.824-13.764 0.930.001 0.93 0.	GCS on admission					
33-14573.3670.834-3.76.49-127152.20.654,-7.396364592.570.754-7.396379-130092.50.33-85.46330-130092.50.33-85.463440092.50.33-85.463440093.50.33-85.463440093.60.03886-89000.3886-8900.35-1.020.3886-890.554.50.390.15-1.02200554.50.390.15-1.02200554.50.390.15-1.022006260Ref0.03322001010.51.021.022001010.30980.314-30.6080.102200101.032.692-11.3890.1121001010.30980.314-30.6080.310211100.613.0980.314-30.6080.310212101.30.9680.314-30.6080.310214101.30.9680.314-30.6080.310215111.30.9680.314-30.6080.316216121214180.348-1.950.316216121214180.46-1.1080.061216121214120.050.061216121314 <td>15</td> <td>7</td> <td>33</td> <td>Ref</td> <td></td> <td><0.001</td>	15	7	33	Ref		<0.001
9-127153.20.654-7.396S845923.5717.964-69.763S12917Ref.0.42330-13963480.110-0.3334,4063480.110-0.33B4,40919Ref.0.38B4,4919Ref.0.38B4,4090.0.0.39.0.15-1.02B4,6000.0.39.0.15-1.02B4,600.0.39.0.15-1.02.0.38B2,006260Ref.0.3322006260Ref.0.3322006260Ref.0.3121006263Ref.0.3121006163Ref.0.31211193.9682.692-12.596.0.15212140.8240.314-30.6080.316No6163Ref.0.16Diabetes mellitus	13–14	5	7	3.367	0.824–13.764	
shale45923,5717,964-69,763Systolic blood pressure<	9–12	7	15	2.2	0.654–7.396	
Systelic blood pressureIIIII\$139-139092.50.13-85.460.110-0.33130-1396348.40.110-0.330.13Diastolic blood pressureI0.380.30.3885-8900000.3887-890.554.560.390.15-10.20.3882001054.60Ref1.052-11.3890.03322001243.4621.052-11.3890.0312200124.03.4621.052-11.3890.0312200143.4621.052-11.3890.0310.0312200143.4621.052-11.3890.0310.0312200143.4621.052-11.3890.0310.0312200149.3463.4690.0310.0312200149.3433.6980.314-30.6080.31022001413.0980.314-30.6080.3100.310211140.8340.343-30.6980.3310.310No52541.60.3160.310No52140.8341.80.345-1.9540.666No544.81.81.60.0680.666No544.81.80.46-1.1080.668No544.81.80.46-1.1080.666No544.81.80.55-6.800.65 <t< td=""><td>≤8</td><td>45</td><td>9</td><td>23.571</td><td>7.964–69.763</td><td></td></t<>	≤8	45	9	23.571	7.964–69.763	
stage17Ref	Systolic blood pressure					
130-39 2140092.50.13-85.46 0-0.33214063480.110-0.33Diastolic blod pressure84900859000.3585-690.5450.390.15-1.0280005450.390.15-1.0220005450.390.15-1.0223001243.4621.052-1.1.38923001243.4621.052-1.1.3892400143.082.692-12.5960.00121149235.8232.692-12.59621149235.8232.692-12.59621149235.8232.692-12.596121143.0980.314-30.6080.310No61627.643.16No62207.643.16No52140.8240.348-1.954No62561.80.746-4.342No52280.2660.66-1.108No62561.80.746-4.342No62568.65No62560.66No631.60.071Yes280.52-6.03No62560.35-6.43No631.60.67No21451.65No21281.65No21281.65N	≤129	1	7	Ref		<0.42
240 Distolic blood pressure63 4848 60.110-0.93 0B4, 89,-90 2900000.3889,-90 2900.50.60.00.05290 2900.50.60.00.05200 22006260Ref0.0332200 22000.260Ref0.0332200 22000.260Ref0.0312200 22000.260Ref0.0322200 22000.20.00.00.01154.1Ref0.0322200 22000.19.00.00.0200 22000.19.00.00.0200 22000.18.10.092-0.2.5960.001201 22000.11.03.0980.300201 22000.18.10.040-0.0580.300201 22000.11.00.00.001No0.20.00.00.00.001No0.20.00.00.00.0100 12001.10.00.00.00.0201 12001.12.00.357-0.20.001None91.12.50.35-0.430.0101 12001.12.60.357-0.20.0101 12001.12.60.357-0.20.012001.12.60.357-0.20.012001.12.60.3	130–139	0	9	2.5	0.13–85.46	
Diastic blood pressureIIIIIsB4,919Ref0.38By-By00029055450.390.15-1.02Random blood glucose000022006260Ref0.03222001243.4621.052-11.38922001243.4621.052-11.38922001243.6620.0312001243.6822.69-12.59621149235.8232.69-12.59621149235.8232.69-12.59621149235.8232.69-12.59621149235.8232.69-12.596211716363Ref11149235.8232.69-12.59621250Ref3.314-30.6080.310No5250Ref11117273736-4.340.696No5250Ref11111211211111111111211241241291111241241250.35-4.331111241241250.35-4.331111241241250.35-4.331111241241250.35-4.331111241241250.35-4.331111241241250	≥140	63	48	0.11	0-0.93	
shap 85-80 909090Ref0.3885-80 90000Random blood glucose002006260Ref0.03322001240Ref0.03322001240Ref0.03222001241Ref<	Diastolic blood pressure					
8§-89 0 0 0 290 55 45 0.39 0.15-1.02 Random blood glucose - 0.033 2.00 0.2 60 Ref 0.032 2200 62 60 Ref 0.032 1.89 2200 12 60 Ref 0.031 1.89 2200 12 60 Ref <0.031	≤84	9	19	Ref		0.38
29055450.390.15-1.02Randon blood glucose6260Ref0.03322001243.4621.052-11.38924001243.4621.052-11.389Leukozyte countRef<.0.01	85–89	0	0			
Random blood glucose 62 60 Ref 0.03 2200 122 40 $3,462$ $1.052-11.390$ Leukocyte count 1 67 Ref $0.021-1390$ Leukocyte count 1 67 Ref $0.021-1390$ Stal 15 863 $2.692-12.596$ 0.010^2 Atrial fibrillation 1 3.932 $2.692-12.596$ 0.310^2 Atrial fibrillation 1 3.932^2 0.600^2 0.931^2 No 3 1 3.932^2 0.931^2 0.310^2^2 Diabetes mellitus 1 3.932^2 0.931^2^2 0.931^2^2 0.931^2^2 No 52 14^2 0.824^2 $0.34^2-1.954^2^2$ 0.931^2^2 No 54^2 4.83^2^2 $0.34^2-1.954^2^2^2$ $0.187^2^2^2^2^2^2^2^2^2^2^2^2^2^2^2^2^2^2^2$	≥90	55	45	0.39	0.15-1.02	
<2006260Ref0.0332200124Ref0.03-11.389210154.1Ref<0.001	Random blood glucose					
22001243 4621.052-11.389Leukoyte count\$114940Ref-1149235.8332.692-12.596-Atrial fibrillationYes313.0980.314-30.6080.310No6163RefDiabetes mellitusYes12140.8240.348-1.9540.660No5250RefYes54481.80.746-4.3420.187No1016RefPysipidemiaYes280.2260.046-1.1080.068No6256RefSide of weaknessNone911RefSide of weaknessKight11281.850.51-6.80-Both side1110.07MusceSide of weaknessSide of weaknessSide of weaknessSide of weaknessSide of side strength (MRC) <td< td=""><td><200</td><td>62</td><td>60</td><td>Ref</td><td></td><td>0.033</td></td<>	<200	62	60	Ref		0.033
Leukocyte count Image: state of the state o	≥200	12	4	3.462	1.052–11.389	
$\$11$ 49 41 Ref < 0.01 $\varkappa 11$ 49 23 5.823 $2.692-12.596$ < 0.01 Atrial fibrillation < 3.098 $0.314-30.608$ 0.310 No 61 63 Ref < 0.01 Diabets mellitus < 130.998 $0.314-30.608$ 0.310 Yes 32 14 0.824 $0.348-1.954$ 0.660 No 52 50 Ref $< 0.016^{-1.080}$ 0.660 No 52 50 Ref $< 0.016^{-1.080}$ 0.660 No 52 86 0.226 $0.046-1.108$ 0.668 No 52 86 0.226 $0.046-1.108$ 0.668 No 52 86 0.226 $0.046-1.108$ 0.068 No 52 86 $0.229-10.248$ 0.001 0.061 No 21 45 Ref 0.07 16 0.07 Side of weakness 12 12 12 0.35 $0.35-4.$	Leukocyte count					
>114923 5.823 $2.692-12.596$ Atrial fbrillationYes31 3.098 $0.314-30.608$ 0.310 No6163RefDiabetes mellitusYes1214 0.824 $0.348^{-1.954}$ 0.660 No5250RefYes1214 0.824 $0.348^{-1.954}$ 0.660 No5250RefYes54481.8 $0.746-4.342$ 0.187 No1016RefPysipidemiaYes28 0.226 $0.046-1.108$ 0.668 No6256RefYes4319 4.850 $2.295-10.248$ <0.001 None215RefSide of weaknessNone911RefSide of weaknessMuscle strength (MRC)-128 1.85 $0.51-6.80$ -562Ref- 0.325 433.86 $0.45-39.76$ 5679 3.86 $0.45-39.76$ -479 3.86	≤11	15	41	Ref		<0.001
Atrial fibrillationImage: second	>11	49	23	5.823	2.692–12.596	
Yes 3 1 3.098 0.314-30.608 0.310 No 61 63 Ref Image: Second Sec	Atrial fibrillation					
No 61 63 Ref Diabetes mellitus	Yes	3	1	3.098	0.314–30.608	0.310
Diabetes mellitus 12 14 0.824 0.348-1.954 0.660 No 52 50 Ref	No	61	63	Ref		
Yes 12 14 0.824 0.348-1.954 0.660 No 52 50 Ref Hypertension - - - Yes 54 48 1.8 0.746-4.342 0.187 No 10 16 Ref Dyslipidemia - - - Yes 2 8 0.226 0.046-1.108 0.068 No 62 56 Ref Yes 43 19 4.850 2.295-10.248 <0.001	Diabetes mellitus					
No 52 50 Ref Hypertension -	Yes	12	14	0.824	0.348–1.954	0.660
Hypertension 54 48 1.8 0.746-4.342 0.187 No 10 160 Ref 7	No	52	50	Ref		
Yes 54 48 1.8 0.746-4.342 0.187 No 10 16 Ref Dyslipidemia 2 8 0.226 0.046-1.108 0.068 No 62 56 Ref	Hypertension		0		<u>,</u>	
No 10 16 Ref Dyslipidemia -	Yes	54	48	1.8	0.746-4.342	0.187
Dysipidemia 2 8 0.226 0.046-1.108 0.068 No 62 56 Ref 7	No	10	16	Ref		
Yes 2 8 0.226 0.046-1.108 0.068 No 62 56 Ref 70	Dyslipidemia		0			
No 62 56 Ref Complications -	Yes	2	8	0.226	0.046-1.108	0.068
Yes 43 19 4.850 2.295-10.248 <0.001 No 21 45 Ref - <td< td=""><td>NO Compliantions</td><td>62</td><td>56</td><td>Ret</td><td></td><td></td></td<>	NO Compliantions	62	56	Ret		
Yes 43 19 4.850 2.295–10.248 <0.001 No 21 45 Ref	Complications			. 0	0	
No 21 45 Ref 6 Side of weakness -	Yes	43	19	4.850 Def	2.295-10.248	<0.001
None 9 11 Ref 0.07 Left 14 24 1.25 0.35-4.43 Right 11 28 1.85 0.51-6.80 Both side 11 1 0.07 0-0.71 Muscle strength (MRC) - - - - 5 6 2 Ref 0.325 4 7 9 3.866 0.45-39.76 3 8 5 1.88 0.19-20.76	NO Side of weakness	21	45	Rer		
None 9 11 Ref 0.07 Left 14 24 1.25 0.35-4.43 Right 11 28 1.85 0.51-6.80 Both side 11 1 0.07 0-0.71 Muscle strength (MRC) 7 9 3.86 0.45-39.76 3 8 5 1.88 0.19-20.76	Side of weakness			Def		0.07
Left 14 24 1.25 0.35-4.43 Right 11 28 1.85 0.51-6.80 Both side 11 1 0.07 0-0.71 Muscle strength (MRC) - - - - 5 6 2 Ref 0.325 4 7 9 3.86 0.45-39.76 3 8 5 1.88 0.19-20.76	Inoffe	9	11	Rei	0.05 / /0	0.07
Nght 11 26 1.65 0.51-0.00 Both side 11 1 0.07 0-0.71 Muscle strength (MRC) - - - - 5 6 2 Ref 0.325 4 7 9 3.86 0.45-39.76 3 8 5 1.88 0.19-20.76	Leit Diaht	14	24	1.25	0.35-4.43	
Dott Side 11 1 0.07 0-0.71 Muscle strength (MRC) - - - - 5 6 2 Ref 0.325 4 7 9 3.86 0.45-39.76 3 8 5 1.88 0.19-20.76	Right	11	20	1.05	0.51-0.00	
5 6 2 Ref 0.325 4 7 9 3.86 0.45-39.76 3 8 5 1.88 0.19-20.76	DULI SILE	11	1	0.07	0-0.71	
5 6 2 Ref 0.325 4 7 9 3.86 0.45-39.76 3 8 5 1.88 0.19-20.76	r	6	2	Dof		0.225
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	5	0	2	2.86	015 2076	0.325
5 5 1.00 0.19 ^{-20.70}	4	/	9	3.00	0.45-39.70	
	3 2	17	5	1.00	0.19-27.70	

(Contd...)

Table 2: The risk factors of mortality in patients with primary intracerebral hemorrhage					
Variable	Dead (64)	Alive (64)	OR	CI	Р
1	16	11	2.06	0.28–18.23	
0	10	11	3.67	0.46–34.99	
Smoking					
Yes	15	14	1.093	0.478-2.502	0.833
No	49	50	Ref		
Length of stay (days)					
≤3	43	6	Ref		<0.001
>3	21	58	0.051	0.019–0.136	
Metabolic encephalopathy					
Yes	10	4	2.778	0.823-9.375	0.089
No	54	60	Ref		
Congestive heart failure					
Yes	1	3	0.323	0.033–3.188	0.310
No	63	61	Ref		
Ventilator assisted					
Yes	8	4	2.143		0.225
No	56	60	Ref	0.611–7.511	

GCS: Glasgow Coma Scale, OR: Odds ratio, CI: Confidence interval, MRC: Medical research council

Table 3: The determinant risk factors ofmortality in patients with primary intracerebralhemorrhage

Variable	OR (adjusted)	95% CI	P
GCS 15	Ref	Ref	0.002
GCS 13–14	4.661	0.632–34.348	0.131
GCS 9–12	4.390	0.745–25.883	0.102
GCS <8	22.410	4.461–112.587	<0.001
High random blood glucose	5.473	0.865–34.614	0.071
High leukocyte count	4.894	1.480–16.179	0.009
Complications	3.502	1.103–11.117	0.033
Length of stay	0.029	0.006–0.141	<0.001

GCS: Glasgow Coma Scale, OR: Odds ratio, CI: Confidence interval

and urinary tract infection). This study confirmed the finding of previous studies that complications will increase the risk of death.^[3,5] Patients with low GCS score have a higher risk of complications and more massive hematoma.^[3,5,6]

The adjusted OR for high random blood glucose is not significantly increase the risk of death. The previous review showed that hyperglycemia is related with other ischemic event in patients with hemorrhagic stroke.^[7] Hyperglycemia also increases the risk of hematoma expansion.^[8] Hyperglycemia in patients with hemorrhagic stroke is related with cytokine activation from the blood extravasation. High cytokine (tumor necrosis factor and interleukin-1) levels are related with higher inflammatory process. High inflammatory process will lead to hyperglycemia condition.^[9]

Our study confirmed that high leukocyte count increases the risk of death. The previous study showed that high leukocyte count is correlated with lower GCS, higher disability, and death.^[10] High leukocyte count is related with higher inflammatory process and parenchymal brain damage.^[11] High leukocyte count in hemorrhagic stroke is a product of stress phenomenon, catecholamine release, and steroid hormone production.^[12] Our study also confirmed that complications increase the death in patients with hemorrhagic stroke. Medical complications (GI bleeding and urinary tract infection) are common in patients with stroke. GI bleeding will cause hypotension and low hemoglobin level. These two conditions will increase the risk of death and disability.^[13] Urinary tract infection is a poor prognosis of stroke. The UTI increases the risk of death, disability, and prolonged length of stay.^[14] Dysphagia and pneumonia also increase the risk of death and disability. Pneumonia also significantly increases the hospital cost and length of stay.^[15]

This study showed that there is an inverse relationship between lengths of stays and mortality. This phenomenon is caused by early death in patients with hemorrhagic stroke. The result is confirmed with previous studies that prolonged length hospital stay is not the risk of death in patients with hemorrhagic stroke.^[16,17] The risk of death in patients with hemorrhagic stroke in prolonged hospital stay is associated with the presence of medical complications and not related with the nature of the hemorrhagic stroke.^[18,19]

The limitation of our study is the short-term follow-up. We only observed the inhospital mortality and do not follow-up the patients. We only studied patients that not being operated. The use of electronic stroke registry and systematic review of electronic medical record are the strength of this study. Further studies should have longer follow-up.

CONCLUSION

This study showed that lower GCS, high leukocyte count, and the presence of complications would increase the risk of mortality. Prevention of complications should be systematically performed for better prognosis.

REFERENCES

1. American Heart Association. Heart Disease and Stroke Statistics-2016 Update a Report From the American Heart Association; 2016.

- American Heart Association. An Updated Definition of Stroke for the 21st Century a Statement for Healthcare Professionals from the American Heart Association/American Stroke Association; 2013.
- 3. Yousuf RM, Fauzi AR, Jamalludin AR, How SH, Amran M, Shahrin Tc, *et al.* Predictors of in-hospital mortality in primary intracerebral hemorrhage in east coast of peninsular Malaysia. Neurol Asia 2012;17:93-9.
- Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: A simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001;32:891-7.
- Sia SF, Tan KS, Waran V. Primary intracerebral haemorrhage in Malaysia: In hospital mortality and Outcome in patients from a hospital based registry. Med J Malaysia 2007;62:308-12.
- Togha M, Bakhtavar K. Factors associated with inhospital mortality following intracerebral hemorrhage: A three-year study in Tehran, Iran. Bio Med Central Neurol 2004;9:1471-2377.
- Fava S, Aquilina O, Azzopardi J, Agius Muscat H, Fenech FF. The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabet Med 1996;13:80-3.
- Song EC, Chu K, Jeong SW, Jung KH, Kim SH, Kim M, et al. Hyperglycemia exacerbates brain edema and perihematomal cell death after intracerebral hemorrhage. Stroke 2003;34:2215-20.
- Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet 2000;355:773-8.
- Asadollahi K, Beeching NJ, Gill GV. Leukocytosis as a predictor for non-infective mortality and morbidity. QJM 2010;103:285-92.
- Sun W, Peacock A, Becker J, Phillips-Bute B, Laskowitz DT, James ML, et al. Correlation of leukocytosis with early neurological deterioration following supratentorial intracerebral

hemorrhage. J Clin Neurosci 2012;19:1096-100.

- Behrouz R, Hafeez S, Miller CM. Admission leukocytosis in intracerebral hemorrhage: Associated factors and prognostic implications. Neurocrit Care 2015;23:370-3.
- Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol 2010;9:105-18.
- Stott DJ, Falconer A, Miller H, Tilston JC, Langhorne P. Urinary tract infection after stroke. QJM 2009;102:243-9.
- Paciaroni M, Mazzotta G, Corea F, Caso V, Venti M, Milia P, et al. Dysphagia following stroke. Eur Neurol 2004;51:162-7.
- Elmer J, Pallin DJ, Liu S, Pearson C, Chang Y, Camargo CA Jr., et al. Prolonged emergency department length of stay is not associated with worse outcomes in patients with intracerebral hemorrhage. Neurocrit Care 2012;17:334-42.
- Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, *et al.* Factors influencing the decline in stroke mortality: A statement from the American heart association/ American stroke association. Stroke 2014;45:315-53.
- Govan L, Langhorne P, Weir CJ, Stroke Unit Trialists Collaboration. Does the prevention of complications explain the survival benefit of organized inpatient (stroke unit) care? Further analysis of a systematic review. Stroke 2007;38:2536-40.
- Ingeman A, Andersen G, Hundborg HH, Svendsen ML, Johnsen SP. In-hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke 2011;42:3214-8.

How to cite this Article: Pinzon RT, Kurniawan A. The determinant of poor prognostic factors in patients with primary intracerebral hemorrhage. Asian Pac. J. Health Sci., 2017; 4(4):163-167.

Source of Support: Nil, Conflict of Interest: None declared.